J
J. Shepherd
Researcher at University of Glasgow
Publications - 52
Citations - 13613
J. Shepherd is an academic researcher from University of Glasgow. The author has contributed to research in topics: Pravastatin & Low-density lipoprotein. The author has an hindex of 22, co-authored 52 publications receiving 13302 citations.
Papers
More filters
Journal ArticleDOI
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group
J. Shepherd,Stuart M. Cobbe,Ian Ford,C. G. Isles,AR Lorimer,Peter W. Macfarlane,J. H. Mckillop,Christopher J. Packard +7 more
TL;DR: Treatment with pravastatin significantly reduced the incidence of myocardial infarction and death from cardiovascular causes without adversely affecting the risk of death from noncardiovascular causes in men with moderate hypercholesterolemia and no history of my Cardiac Infarction.
Journal ArticleDOI
West of Scotland Coronary Prevention Study: Identification of high-risk groups and comparison with other cardiovascular intervention trials
J. Shepherd,Stuart M. Cobbe,AR Lorimer,James H. McKillop,Jane B. Ford,Christopher J. Packard,Peter W. Macfarlane,Chris Isles,MF Oliver,A. F. Lever,BW Brown,Jgg Ledingham,SJ Pocock,BM Rifkind,B. D. Vallance,David Ballantyne,L Anderson,D Duncan,Sharon Kean,A Lawrence,John J. McGrath,K Montgomery,John Norrie,M Percy,E Pomphrey,Andrew J. O. Whitehouse,Peter Cameron,P Parker,F Porteous,L Fletcher,C Kilday,D Shoat,S Latif,James L. Kennedy,M A Bell,R Birrell,M Mellies,J Meyer,W Campbell +38 more
Journal ArticleDOI
Plasma Leptin and the Risk of Cardiovascular Disease in the West of Scotland Coronary Prevention Study (WOSCOPS)
A M Wallace,Alex D. McMahon,Christopher J. Packard,A Kelly,J. Shepherd,Allan Gaw,Naveed Sattar +6 more
TL;DR: It is shown, for the first time, in a large prospective study that leptin is a novel, independent risk factor for coronary heart disease.
Journal Article
Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS)
Chris J. Packard,J. Shepherd,Stuart M. Cobbe,Jane B. Ford,Chris Isles,James H. McKillop,Peter W. Macfarlane,AR Lorimer,John Norrie,W Scotland Coronary Prevention Study Grp +9 more
TL;DR: There is no CHD risk reduction unless LDL levels are reduced, but a fall in the range of 24% is sufficient to produce the full benefit in patients taking this dose of pravastatin, which is proportionally the same regardless of baseline lipid phenotype.
Journal ArticleDOI
The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials
Jasper J. Brugts,Tuncay Yetgin,Sanne E. Hoeks,Antonio M. Gotto,J. Shepherd,Rudi G. J. Westendorp,A.J.M. de Craen,R. H. Knopp,Haruo Nakamura,Paul M. Ridker,R. Van Domburg,Jaap W. Deckers +11 more
TL;DR: In patients without established cardiovascular disease but with cardiovascular risk factors, statin use was associated with significantly improved survival and large reductions in the risk of major cardiovascular events.